drugset / Trial / NCT01147107
Hepatic Safety of Raltegravir Versus Efavirenz as HIV Therapy for Patients With HIV and HCV Coinfection
Phase 4
Completed
80 enrolled
University of Hawaii
Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam · collabOxford University Clinical Research Unit, Vietnam · collabViet Tiep Hospital · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
The main objective is to evaluate the hepatic safety of raltegravir when compared to efavirenz, both in combination with tenofovir and emtricitabine as first-line HIV treatment in patients with HIV and hepatitis C coinfection.
Timeline
- Start
- 2014-02
- Primary completion
- 2016-06-01
- Completion
- 2021-06-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Efavirenz | Other / unclassified | 600 mg | Oral |
| Subject | Raltegravir | Other / unclassified | 400 mg | Oral |
| Background | Tenofovir disoproxil fumarate | Small molecule | 300 mg | Oral |
| Background | emtricitabine | Other / unclassified | 200 mg | Oral |